Highlights of the 9th ESC Congress.
S. Sinan Ozalp (Turkey), President of the Organizing Committee.
I think once again, that the ESC held a successful meeting, the 9th Congress, with the title ‘Improving Life Quality Through Contraception and Reproductive Health Care’.
The highest attendance in ESC history was achieved, reaching over 1.800 participants from over 80 countries. The ‘top five’ countries in greatest participation were Turkey, Spain, France, Russia and the United Kingdom.
This congress was the the first congress with simultaneous translation available in two languages, Turkish and Russian. I believe this support helped our colleagues from Russia and other surrounding countries to participate actively.
Forums, Free Communications, Plenary Sessions with Keynote Lectures, Meet the Experts Sessions, Posters, Society Sessions, State of the Art Sessions and Symposia were part of the scientific program. This congress attracted a high number of free communication and poster abstracts, requiring a peer-reviewed assessment process, leading to a very high standard of free communication presentations and posters.
Following the tradition of ESC Congresses, the scientific program covered all aspects of reproductive health and contraception from basic to clinical research.
The topics contained the newest data on contraception, reproductive health and sexual health. Three of the main topics of interest were, new developments in male hormonal contraception for men, recent developments in abortion techniques and contraception without bleeding.
Hormonal contraception for men was discussed in details by distinguished speakers in the field. GnRh analogues, GnRh immunization, synthetic progestins and androgen preparations are the hormonal contraceptive options for men.
Regarding medical abortion methods, the optimal dose of mifepristone and best choice of prostaglandin analogues, at different gestations and acceptability were discussed by leading experts in several sessions. Another important topic of the congress was contraception without bleeding.
The acceptablility, continuation rates, as well as efficacy and side effects of extended use of 30µg EE + 150µg levonorgestrel, 91 day regimen, was discussed in detail. Long-term efficacy and safety of these contraceptive methods need to be addressed. In this congress, current knowledge, practice and thoughts about contraception and reproductive health care were shared by the participants.
View the abstracts of the 9th ESC Congress in the online abstractbook.